Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

SK backs expansion at Pennsylvania cell and gene therapy venture

by Rick Mullin
November 26, 2021 | A version of this story appeared in Volume 99, Issue 43

The Center for Breakthrough Medicines (CBM), a cell and gene therapy contract services firm, plans to expand research and manufacturing with an investment from SK. CBM was established in 2019 by the Discovery Labs after the latter acquired a GlaxoSmithKline R&D center in King of Prussia, Pennsylvania. CBM says it will hire 2,000 people over the next 4 years. SK, a South Korean company with investments in life sciences, energy, and other industries, says it will partner with CBM in providing cell and gene therapy services.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.